Compare Freeport-McMoRan Inc (FCX) vs Mesoblast Limited (MESO) Price & Performance

FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.

FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.

MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.

The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.